BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 279] [Cited by in F6Publishing: 180] [Article Influence: 139.5] [Reference Citation Analysis]
Number Citing Articles
1 Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, Khalid U. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA 2021;325:1545-55. [PMID: 33877270 DOI: 10.1001/jama.2021.0716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Ishikura M, Endo A, Koshino K, Kagawa Y, Tanabe K. Development of Alveolar Hemorrhage in a Patient with Acute Myocardial Infarction Complicated with Essential Thrombocythemia. Am J Case Rep 2021;22:e928409. [PMID: 33558452 DOI: 10.12659/AJCR.928409] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ge Z, Gao XF, Kan J, Kong XQ, Zuo GF, Ye F, Tian NL, Lin S, Liu ZZ, Shao YB, He YQ, Wen SY, Yang Q, Xia Y, Wang ZZ, Xiao PX, Li F, Zeng HS, Yang S, Wang Y, Tao L, Gao DS, Qu H, Qian XS, Han YL, Chen F, Zhang JJ, Chen SL. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Am Heart J 2021;236:49-58. [PMID: 33621541 DOI: 10.1016/j.ahj.2021.02.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fukaya H, Ako J, Yasuda S, Kaikita K, Akao M, Matoba T, Nakamra M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H. Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation. Heart 2021:heartjnl-2021-319321. [PMID: 34261738 DOI: 10.1136/heartjnl-2021-319321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Verdoia M, Gioscia R, De Luca G. Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome. J Geriatr Cardiol 2021;18:210-8. [PMID: 33907551 DOI: 10.11909/j.issn.1671-5411.2021.03.010] [Reference Citation Analysis]
6 Saito Y, Kobayashi Y, Tanabe K, Ikari Y. Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. Cardiovasc Interv and Ther 2020;35:19-29. [DOI: 10.1007/s12928-019-00633-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
7 Verdoia M, Khedi E, Suryapranata H, De Luca G. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. Rev Esp Cardiol (Engl Ed) 2021;74:140-8. [PMID: 32482558 DOI: 10.1016/j.rec.2020.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Buccheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety 2019;18:1171-89. [DOI: 10.1080/14740338.2019.1680637] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
9 Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J 2021;42:339-51. [PMID: 33367641 DOI: 10.1093/eurheartj/ehaa824] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
10 Shiraishi J, Ito F, Yoshimura J, Kirii Y, Kataoka E, Ozawa T, Ito D, Kojima A, Kimura M, Kishita E, Nakagawa Y, Hyogo M, Sawada T. Stentless Interventional Procedure Using Rotational Atherectomy and Drug-Coated Balloon for Noncalcified De Novo Lesions. CJC Open 2021;3:714-22. [PMID: 34169250 DOI: 10.1016/j.cjco.2021.01.004] [Reference Citation Analysis]
11 Ho MY, Chen PW, Feng WH, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HW, Lin SH, Hsieh IC, Li YH. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. PLoS One 2021;16:e0251109. [PMID: 33979377 DOI: 10.1371/journal.pone.0251109] [Reference Citation Analysis]
12 Briguori C. Early P2Y12 Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin? Circ Cardiovasc Interv 2021;14:e010880. [PMID: 34003664 DOI: 10.1161/CIRCINTERVENTIONS.121.010880] [Reference Citation Analysis]
13 Changal KH, Mir T, Khan S, Nazir S, Elzanatey A, Meenakshisundaram C, Mubbasher S, Sheikh MA. Drug-Eluting Stents Versus Bare-Metal Stents in Large Coronary Artery Revascularization: Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2021;23:42-9. [DOI: 10.1016/j.carrev.2020.07.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Swan D, Newland A, Rodegheiro F, Thachil J. Thrombosis in immune thrombocytopenia - current status and future perspectives. Br J Haematol 2021;194:822-34. [PMID: 33822358 DOI: 10.1111/bjh.17390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual Antiplatelet Therapy in Coronary Artery Disease. Cardiol Ther 2020;9:349-61. [PMID: 32804330 DOI: 10.1007/s40119-020-00197-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kearney A, Linden K, Savage P, Menown IBA. Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials. Adv Ther 2021;38:2170-200. [PMID: 33844133 DOI: 10.1007/s12325-021-01711-z] [Reference Citation Analysis]
17 Sun Y, Liu X, Xu Y. The optimal duration of dual antiplatelet therapy in East Asian patients undergoing percutaneous coronary intervention with drug-eluting stents: a meta-analysis of randomized trials. Coron Artery Dis 2021;32:119-30. [PMID: 32639246 DOI: 10.1097/MCA.0000000000000921] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews 2020;39:100619. [DOI: 10.1016/j.blre.2019.100619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 O'Donoghue ML, Murphy SA, Sabatine MS. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Circulation 2020;142:538-45. [PMID: 32551860 DOI: 10.1161/CIRCULATIONAHA.120.046251] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Article Influence: 37.0] [Reference Citation Analysis]
20 Xu Y, Shen Y, Chen D, Zhao P, Jiang J. Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. J Interv Cardiol 2021;2021:9934535. [PMID: 34035674 DOI: 10.1155/2021/9934535] [Reference Citation Analysis]
21 Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J 2020;228:1-7. [PMID: 32739652 DOI: 10.1016/j.ahj.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wang X, Sun M, Qu A, Wang W, Lu M, Guo X, Chen C, Hao C, Xu L, Xu C, Kuang H. Improved Reactive Oxygen Species Generation by Chiral Co3 O4 Supraparticles under Electromagnetic Fields. Angew Chem Int Ed Engl 2021;60:18240-6. [PMID: 34018664 DOI: 10.1002/anie.202105675] [Reference Citation Analysis]
23 Van den Eynde J, Bennett J, McCutcheon K, Adriaenssens T, Desmet W, Dubois C, Sinnaeve P, Verbelen T, Jacobs S, Oosterlinck W. Heart team 2.0: A decision tree for minimally invasive and hybrid myocardial revascularization. Trends Cardiovasc Med 2021;31:382-91. [PMID: 32712328 DOI: 10.1016/j.tcm.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Andò G, Costa F. Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. International Journal of Cardiology 2020;302:95-102. [DOI: 10.1016/j.ijcard.2019.12.054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
25 Capranzano P, Angiolillo DJ. Antithrombotic Management of Elderly Patients With Coronary Artery Disease. JACC Cardiovasc Interv 2021;14:723-38. [PMID: 33826494 DOI: 10.1016/j.jcin.2021.01.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P; SIDNEY Collaboration. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv 2021;14:444-56. [PMID: 33602441 DOI: 10.1016/j.jcin.2020.11.046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy 2021;53:947-69. [PMID: 34359080 DOI: 10.1055/a-1547-2282] [Reference Citation Analysis]
28 Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE, Lee KK. Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 2021;8:e001707. [PMID: 34341097 DOI: 10.1136/openhrt-2021-001707] [Reference Citation Analysis]
29 Ishida M, Takahashi F, Goto I, Niiyama M, Saitoh H, Sakamoto T, Maegawa Y, Osaki T, Nishiyama O, Endo H, Sakamoto R, Kojima T, Koeda Y, Kimura T, Itoh T, Morino Y; REIWA investigators. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. Cardiovasc Interv Ther 2020;35:398-404. [PMID: 32776221 DOI: 10.1007/s12928-020-00694-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Maillard L, de Labriolle A, Brasselet C, Faurie B, Durel N, de Poli F, Bosle S, Madiot H, Berland J, Belle L. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high-risk patients: The e-Cobra study. Catheter Cardiovasc Interv 2021;98:45-54. [PMID: 32548891 DOI: 10.1002/ccd.29065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
31 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.Intern Med. 2020;59:311-321. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-3719] [Reference Citation Analysis]
32 McClure JD, Ramsay JC, Berry C. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Heart Assoc 2020;9:e017109. [PMID: 32779497 DOI: 10.1161/JAHA.120.017109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
33 Bhattarai M, Ibrahim AM, Salih M, Tandan N, Al-akchar M, Ayan M, Kulkarni A, Hafiz AM. Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Control Trials. Journal of Cardiovascular Pharmacology 2020;76:574-83. [DOI: 10.1097/fjc.0000000000000902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 De Luca L, Valgimigli M. Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother 2021;7:352-9. [PMID: 33175148 DOI: 10.1093/ehjcvp/pvaa107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, Farhan S, Gurbel P, Gibson CM, Fuster V, Mehran R, Badimon JJ. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll Cardiol 2020;75:578-86. [PMID: 32057371 DOI: 10.1016/j.jacc.2019.11.056] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 32.0] [Reference Citation Analysis]
36 Cho JY, Lee SY, Yun KH, Kim BK, Hong SJ, Ko JS, Rhee SJ, Oh SK, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial. J Am Heart Assoc 2021;10:e019630. [PMID: 33739127 DOI: 10.1161/JAHA.120.019630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Chen PW, Feng WH, Ho MY, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HLS, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. J Clin Med 2020;9:E1657. [PMID: 32492818 DOI: 10.3390/jcm9061657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Sinnaeve PR, Adriaenssens T. Dual Antiplatelet Therapy De-escalation Strategies. Am J Cardiol 2021;144 Suppl 1:S23-31. [PMID: 33706987 DOI: 10.1016/j.amjcard.2020.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Capodanno D, Morice M, Angiolillo DJ, Bhatt DL, Byrne RA, Colleran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim H, Kimura T, Konishi A, Leon MB, Magee PA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology 2020;76:1468-83. [DOI: 10.1016/j.jacc.2020.06.085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
41 Lu DY, Steitieh D, Feldman DN, Cheung JW, Wong SC, Halazun H, Halazun KJ, Amin N, Wang J, Chae J, Wilensky RL, Kim LK. Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A Nationwide Database). Am J Cardiol 2020;125:1295-304. [PMID: 32145896 DOI: 10.1016/j.amjcard.2020.01.052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kanenawa K, Yamaji K, Tashiro H, Domei T, Ando K, Watanabe H, Kimura T. Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial. Circ Cardiovasc Interv 2021;14:e010007. [PMID: 33541100 DOI: 10.1161/CIRCINTERVENTIONS.120.010007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Wu XT, He RR, Liang SZ, Ye GY, Ding SB. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis. Minerva Med 2020;111:173-80. [PMID: 32338843 DOI: 10.23736/S0026-4806.19.06281-5] [Reference Citation Analysis]
44 Guedeney P, Collet JP. Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. J Clin Med 2020;9:E3474. [PMID: 33126578 DOI: 10.3390/jcm9113474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
45 Malik AH, Yandrapalli S, Shetty SS, Aronow WS, Cooper HA, Panza JA. Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention. Am J Cardiol 2020;127:25-9. [PMID: 32389351 DOI: 10.1016/j.amjcard.2020.04.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
46 Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation 2020;142:1425-36. [PMID: 32795096 DOI: 10.1161/CIRCULATIONAHA.120.046308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 27.0] [Reference Citation Analysis]
47 Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2020;9:E680. [PMID: 32138287 DOI: 10.3390/jcm9030680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
48 Capodanno D, Di Maio M, Greco A, Bhatt DL, Gibson CM, Goette A, Lopes RD, Mehran R, Vranckx P, Angiolillo DJ. Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2020;9:e017212. [PMID: 32805186 DOI: 10.1161/JAHA.120.017212] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
49 Hong S, Ahn C, Kim J, Kim B, Ko Y, Choi D, Jang Y, Hong M. Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients. European Heart Journal - Cardiovascular Pharmacotherapy 2020. [DOI: 10.1093/ehjcvp/pvaa119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Walker J, Cattaneo M, Badimon L, Agnelli G, Chan AT, Lanas A, Rocca B, Rothwell P, Patrignani P, Langley R, Vilahur G, Cosentino F. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience 2020;14:998. [PMID: 32153653 DOI: 10.3332/ecancer.2020.998] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Chao CJ, Shanbhag A, Chiang CC, Girardo ME, Seri AR, Khalid MU, Rayfield C, O'Shea MP, Fatunde O, Fortuin FD. Baseline thrombocytopenia in acute coronary syndrome: The lower, the worse. Int J Cardiol 2021;332:1-7. [PMID: 33785391 DOI: 10.1016/j.ijcard.2021.03.059] [Reference Citation Analysis]
52 Vogel B, Baber U, Cohen DJ, Sartori S, Sharma SK, Angiolillo DJ, Farhan S, Goel R, Zhang Z, Briguori C, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Han YL, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta SR, Moliterno D, Ohman EM, Sardella G, Witzenbichler B, Gibson CM, Pocock S, Huber K, Mehran R. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol 2021. [PMID: 33991416 DOI: 10.1001/jamacardio.2021.1720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Yun KH, Lee SY, Cho BR, Jang WJ, Song YB, Oh JH, Chun WJ, Park YH, Im ES, Jeong JO, Oh SK, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC, Hahn JY; SMART‐CHOICE Investigators [Link]. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial. J Am Heart Assoc 2021;10:e018366. [PMID: 33345567 DOI: 10.1161/JAHA.120.018366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Angiolillo DJ, Baber U, Sartori S, Briguori C, Dangas G, Cohen DJ, Mehta SR, Gibson CM, Chandiramani R, Huber K, Kornowski R, Weisz G, Kunadian V, Oldroyd KG, Ya-ling H, Kaul U, Witzenbichler B, Dudek D, Sardella G, Escaned J, Sharma S, Shlofmitz RA, Collier T, Pocock S, Mehran R. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 2020;75:2403-13. [DOI: 10.1016/j.jacc.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 29.0] [Reference Citation Analysis]
55 Feng WH, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin? Acta Cardiol Sin 2021;37:1-8. [PMID: 33488022 DOI: 10.6515/ACS.202101_37(1).20200806A] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Khan SU, Khan MZ, Khan MS, Mahmood A, Kalra A, Kaluski E, Michos ED, Alkhouli M. De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies. Eur Heart J Cardiovasc Pharmacother 2021;7:209-15. [PMID: 32271872 DOI: 10.1093/ehjcvp/pvaa025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kao CC, Wu MS, Chuang MT, Lin YC, Huang CY, Chang WC, Chen CW, Chang TH. Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. PLoS One 2021;16:e0255645. [PMID: 34347826 DOI: 10.1371/journal.pone.0255645] [Reference Citation Analysis]
58 Zhang WJ, Qiao X, Guo WF, Liang XY, Li Y, Wang ZL. Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 2021;8:615396. [PMID: 33614748 DOI: 10.3389/fcvm.2021.615396] [Reference Citation Analysis]
59 Giannini F, Pagnesi M, Campo G, Donahue M, Ferri LA, Briguori C, Stefanini GG, Scardala R, Sardella G, De Rosa S, Figini F, Monello A, Pastormerlo LE, Testa L, Nicolino A, Ielasi A, Durante A, Leone A, Tzanis G, Mangieri A, Ciccarelli G, Briani M, Reimers B, Ceccacci A, Indolfi C, Sheiban I, Palmieri C, Bedogni F, Tespili M, Latib A, Gallo F, Colombo A. Italian Multicenter Registry of Bare Metal Stent Use in Modern Percutaneous Coronary Intervention Era (AMARCORD): A multicenter observational study. Catheter Cardiovasc Interv 2021;97:411-20. [PMID: 32198845 DOI: 10.1002/ccd.28798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Simonsson M, Wallentin L, Alfredsson J, Erlinge D, Hellström Ängerud K, Hofmann R, Kellerth T, Lindhagen L, Ravn-fischer A, Szummer K, Ueda P, Yndigegn T, Jernberg T. Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. European Heart Journal 2020;41:833-43. [DOI: 10.1093/eurheartj/ehz593] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
61 Shima Y, Miura K, Shimada T, Ohya M, Murai R, Kubo S, Tada T, Tanaka H, Fuku Y, Kadota K. Impact of ischemic risk factors on long-term outcomes in patients with and without high bleeding risk. Int J Cardiol 2021;326:12-8. [PMID: 33152414 DOI: 10.1016/j.ijcard.2020.10.073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, Chen SL, Bo Z, Goto S, Kimura T, Yasuda S, Chen WJ, Chan M, Aradi D, Geisler T, Gorog DA, Sibbing D, Lip GYH, Angiolillo DJ, Gurbel PA, Jeong YH. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thromb Haemost 2021;121:422-32. [PMID: 33171520 DOI: 10.1055/s-0040-1718729] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
63 Yamamoto K, Shiomi H, Morimoto T, Kadota K, Tada T, Takeji Y, Matsumura-Nakano Y, Yoshikawa Y, Imada K, Domei T, Kaneda K, Taniguchi R, Ehara N, Nawada R, Natsuaki M, Yamaji K, Toyofuku M, Kanemitsu N, Shinoda E, Suwa S, Iwakura A, Tamura T, Soga Y, Inada T, Matsuda M, Koyama T, Aoyama T, Sato Y, Furukawa Y, Ando K, Yamazaki F, Komiya T, Minatoya K, Nakagawa Y, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-3 investigators. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graftinge Among Patients with Unprotected Left Main Coronary Artery Disease in the New-Generation Drug-Eluting Stents Era (From the CREDO-Kyoto PCI/CABG Registry Cohort-3). Am J Cardiol 2021;145:47-57. [PMID: 33454345 DOI: 10.1016/j.amjcard.2020.12.078] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tan JWC, Chew DP, Brieger D, Eikelboom J, Montalescot G, Ako J, Kim BK, Quek DK, Aitken SJ, Chow CK, Chour S, Tse HF, Kaul U, Firdaus I, Kubo T, Liew BW, Chong TT, Sin KY, Yeh HI, Buddhari W, Chunhamaneewat N, Hasan F, Fox KA, Nguyen QN, Lo ST. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. Eur Cardiol 2021;16:e26. [PMID: 34249148 DOI: 10.15420/ecr.2020.45] [Reference Citation Analysis]
65 Rath D, Geisler T. Optimal antiplatelet and anticoagulation strategies in acute coronary syndromes. Herz 2020;45:528-36. [PMID: 32507904 DOI: 10.1007/s00059-020-04947-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Pan G, Chang L, Zhang J, Liu Y, Hu L, Zhang S, Zhang J, Qiao J, Jakopin Ž, Hu H, Dong J, Ding Z. GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI. Biochem Pharmacol 2021;183:114315. [PMID: 33152345 DOI: 10.1016/j.bcp.2020.114315] [Reference Citation Analysis]
67 Mehran R, Cao D, Baber U. Ticagrelor Monotherapy After Coronary Stenting. Journal of the American College of Cardiology 2019;74:2235-7. [DOI: 10.1016/j.jacc.2019.08.1037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
68 Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, Otsuka T, Praz F, Siontis GCM, Moro C, Stortecky S, Billinger M, Valgimigli M, Pilgrim T, Windecker S, Suter T, Räber L. Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. JACC CardioOncol 2019;1:145-55. [PMID: 34396175 DOI: 10.1016/j.jaccao.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
69 Zhang WJ, Qiao X, Liang XY, Li Y, Yang RR, Wang ZL. Efficacy and safety of short-term 1-3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. Platelets 2021;32:582-90. [PMID: 32627616 DOI: 10.1080/09537104.2020.1786039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Ono M, Takahashi K, Gao C, Kawashima H, Wu X, Hara H, Wang R, Wykrzykowska JJ, Piek JJ, Sharif F, Serruys PW, Wijns W, Onuma Y. The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program. Future Cardiol 2021;17:593-607. [PMID: 33258702 DOI: 10.2217/fca-2020-0063] [Reference Citation Analysis]
71 Valgimigli M, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando K, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Jüni P, Mehran R. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 2021;373:n1332. [PMID: 34135011 DOI: 10.1136/bmj.n1332] [Reference Citation Analysis]
72 Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol 2020;19:179. [PMID: 33066794 DOI: 10.1186/s12933-020-01153-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Wang HY, Mo R, Guan CD, Wang Y, Zhao YY, Xie LH, Zhang R, Cai ZX, Xu B, Dou KF. Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome. Catheter Cardiovasc Interv 2021. [PMID: 33909311 DOI: 10.1002/ccd.29741] [Reference Citation Analysis]
74 Wiebe J, Ndrepepa G, Kufner S, Lahmann AL, Xhepa E, Kuna C, Voll F, Gosetti R, Laugwitz KL, Joner M, Kastrati A, Cassese S. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e018304. [PMID: 33410332 DOI: 10.1161/JAHA.120.018304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Natsuaki M, Morimoto T, Yamamoto E, Watanabe H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Hanaoka KI, Tanabe K, Kozuma K, Kimura T; STOPDAPT trial investigators. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. PLoS One 2020;15:e0227612. [PMID: 32210433 DOI: 10.1371/journal.pone.0227612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Vitolo M, Javed S, Capodanno D, Rubboli A, Boriani G, Lip GYH. Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy 2020;18:587-600. [DOI: 10.1080/14779072.2020.1808463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Liang XY, Li Y, Qiao X, Zhang WJ, Wang ZL. Clinical Outcomes of Very Short Term Dual Antiplatelet Therapy in Patients With or Without Diabetes Undergoing Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Cardiovasc Med 2021;8:655718. [PMID: 34277725 DOI: 10.3389/fcvm.2021.655718] [Reference Citation Analysis]
78 Guedeney P, Collet JP. Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. Thromb Haemost 2021;121:854-66. [PMID: 33506483 DOI: 10.1055/s-0040-1722188] [Reference Citation Analysis]
79 Guo W, Chen X, Hao Y, Liu Q, Peng C, Zhao L, Feng Z, Wang X, Ruan H, Li L. Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. Aging (Albany NY) 2020;12:12930-42. [PMID: 32611835 DOI: 10.18632/aging.103359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Migita S, Kitano D, Li Y, Koyama Y, Shimodai-Yamada S, Onishi A, Fuchimoto D, Suzuki S, Nakamura Y, Matsuyama TA, Hirota S, Sakuma M, Tsujimoto M, Hirayama A, Okumura Y, Hao H. Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model. Sci Rep 2021;11:6281. [PMID: 33737695 DOI: 10.1038/s41598-021-85740-2] [Reference Citation Analysis]
81 Yang H, Zhang F, Yang J, Zheng M, Cao R, Dai Y, Li C, Yao K, Qian J, Ge J; TARGET DAPT trial investigators. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial. BMJ Open 2019;9:e033774. [PMID: 31852711 DOI: 10.1136/bmjopen-2019-033774] [Reference Citation Analysis]
82 Marquis-gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, Wallentin L, Steg PG, Lopes RD, Storey RF, Goodman SG, Mahaffey KW, Tricoci P, White HD, Armstrong PW, Ohman EM, Alexander JH, Roe MT. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology 2020;76:162-71. [DOI: 10.1016/j.jacc.2020.05.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
83 Shiraishi J, Kataoka E, Ozawa T, Shiraga A, Ikemura N, Matsubara Y, Nishimura T, Ito D, Kojima A, Kimura M, Kishita E, Nakagawa Y, Hyogo M, Sawada T. Angiographic and Clinical Outcomes After Stent-less Coronary Intervention Using Rotational Atherectomy and Drug-Coated Balloon in Patients with De Novo Lesions. Cardiovasc Revasc Med 2020;21:647-53. [PMID: 31494063 DOI: 10.1016/j.carrev.2019.08.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
84 Serruys PW, Ono M, Garg S, Hara H, Kawashima H, Pompilio G, Andreini D, Holmes DR Jr, Onuma Y, King Iii SB. Percutaneous Coronary Revascularization: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol 2021;78:384-407. [PMID: 34294273 DOI: 10.1016/j.jacc.2021.05.024] [Reference Citation Analysis]
85 Serruys PW, Takahashi K, Chichareon P, Onuma Y. Twilight, the Dawn of a New Era of Aspirin-Free PCI? Journal of the American College of Cardiology 2020;75:2425-9. [DOI: 10.1016/j.jacc.2020.03.071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
86 Nakamura M, Iijima R. Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable. J Cardiol 2021;78:91-8. [PMID: 33358236 DOI: 10.1016/j.jjcc.2020.12.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Lee PH, Park S, Nam H, Kang DY, Kang SJ, Lee SW, Kim YH, Park SW, Lee CW. Intracranial Bleeding After Percutaneous Coronary Intervention: Time-Dependent Incidence, Predictors, and Impact on Mortality. J Am Heart Assoc 2021;10:e019637. [PMID: 34323117 DOI: 10.1161/JAHA.120.019637] [Reference Citation Analysis]
88 Ibanez B, Roque D, Price S. The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care. Eur Heart J 2021;42:884-95. [PMID: 33388774 DOI: 10.1093/eurheartj/ehaa1090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
89 Sharma G, Feldman DI, Bittl JA. Moving Toward Ticagrelor Monotherapy: Like Boats Against the Current. JACC Cardiovasc Interv 2021;14:1447-9. [PMID: 34238554 DOI: 10.1016/j.jcin.2021.05.013] [Reference Citation Analysis]
90 Wang R, Wu S, Gamal A, Gao C, Hara H, Kawashima H, Ono M, van Geuns RJ, Vranckx P, Windecker S, Onuma Y, Serruys PW, Garg S. Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. Eur Heart J Cardiovasc Pharmacother 2021:pvab035. [PMID: 33930107 DOI: 10.1093/ehjcvp/pvab035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzatti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, Valgimigli M. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. Int J Cardiol 2021;337:1-8. [PMID: 34000356 DOI: 10.1016/j.ijcard.2021.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Knijnik L, Fernandes M, Rivera M, Cardoso R, Goyal A, Liberman H, Sperling LS, McDaniel MC. Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting. Am J Cardiol 2021;151:25-9. [PMID: 34049672 DOI: 10.1016/j.amjcard.2021.04.014] [Reference Citation Analysis]
93 Collet J, Montalescot G, Zeitouni M. Aspirin-Free Strategies After PCI. Journal of the American College of Cardiology 2019;74:2028-31. [DOI: 10.1016/j.jacc.2019.08.998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, Van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut 2021;70:1611-28. [PMID: 34362780 DOI: 10.1136/gutjnl-2021-325184] [Reference Citation Analysis]
95 Jacobsen AP, Raber I, McCarthy CP, Blumenthal RS, Bhatt DL, Cusack RW, Serruys PWJC, Wijns W, McEvoy JW. Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted? Circulation 2020;142:1579-90. [PMID: 32886529 DOI: 10.1161/CIRCULATIONAHA.120.045695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
96 Koyama S, Yamashita A, Matsuura Y, Saito Y, Maekawa K, Gi T, Kitamura K, Asada Y. Intracellular glutamine level determines vascular smooth muscle cell-derived thrombogenicity. Atherosclerosis 2021;328:62-73. [PMID: 34102425 DOI: 10.1016/j.atherosclerosis.2021.05.012] [Reference Citation Analysis]
97 Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, Choi KH, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Lee SH, Hahn JY. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. J Korean Med Sci 2021;36:e106. [PMID: 33904262 DOI: 10.3346/jkms.2021.36.e106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Della Bona R, Canepa M, Ameri P, Crea F, Porto I. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2021;7:86-93. [PMID: 31942965 DOI: 10.1093/ehjcvp/pvaa001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
99 Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Takeji Y, Kadota K, Imada K, Toyofuku M, Kanemitsu N, Shinoda E, Suwa S, Iwakura A, Tamura T, Soga Y, Inada T, Matsuda M, Koyama T, Aoyama T, Kato E, Sato Y, Furukawa Y, Ando K, Yamazaki F, Komiya T, Minatoya K, Nakagawa Y, Kimura T. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Versus Without Chronic Kidney Disease. Am J Cardiol 2021;145:37-46. [PMID: 33454346 DOI: 10.1016/j.amjcard.2020.12.079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, Hilliard AA, Bharadwaj AS, Chadi Alraies M, Mohamed M, Bhatt DL, Mamas MA. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;42:1019-34. [PMID: 33681960 DOI: 10.1093/eurheartj/ehaa1032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
101 Alasnag M, Jones TL, Hanfi Y, Ryan N. Sex-based outcomes in contemporary antiplatelet therapy trials. Open Heart 2021;8:e001761. [PMID: 34321335 DOI: 10.1136/openhrt-2021-001761] [Reference Citation Analysis]
102 Costa GF, Costa M, Gonçalves L, Teixeira R. Antiplatelet therapy after transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2021:ezab250. [PMID: 34148077 DOI: 10.1093/ejcts/ezab250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Benenati S, Crimi G, Canale C, Pescetelli F, De Marzo V, Vergallo R, Galli M, Della Bona R, Canepa M, Ameri P, Crea F, Porto I. Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis. Eur Heart J Cardiovasc Pharmacother 2020:pvaa127. [PMID: 33135064 DOI: 10.1093/ehjcvp/pvaa127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
104 Fontana P, Roffi M, Reny JL. Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. J Clin Med 2020;9:E194. [PMID: 31936845 DOI: 10.3390/jcm9010194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
105 Gerstein NS, Albrechtsen CL, Mercado N, Cigarroa JE, Schulman PM. A Comprehensive Update on Aspirin Management During Noncardiac Surgery. Anesth Analg 2020;131:1111-23. [PMID: 32925332 DOI: 10.1213/ANE.0000000000005064] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Morimoto T, Uchida K, Sakakibara F, Kinjo N, Ueda S. Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice. Pharmacoepidemiol Drug Saf 2021;30:1321-31. [PMID: 33715291 DOI: 10.1002/pds.5228] [Reference Citation Analysis]
107 Shoda K, Enomoto Y, Egashira Y, Kinoshita T, Mizutani D, Iwama T. Long-term complications after stent assist coiling dependent on clopidogrel response. BMC Neurol 2021;21:247. [PMID: 34182941 DOI: 10.1186/s12883-021-02270-0] [Reference Citation Analysis]
108 Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, Džavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han Y, Pocock S, Gibson CM, Mehran R. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal 2020;41:3533-45. [DOI: 10.1093/eurheartj/ehaa670] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 26.0] [Reference Citation Analysis]
109 Giallauria F, Di Lorenzo A, Venturini E, Pacileo M, D'Andrea A, Garofalo U, De Lucia F, Testa C, Cuomo G, Iannuzzo G, Gentile M, Nugara C, Sarullo FM, Marinus N, Hansen D, Vigorito C. Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. J Clin Med 2021;10:1696. [PMID: 33920796 DOI: 10.3390/jcm10081696] [Reference Citation Analysis]
110 Ishihara T, Sotomi Y, Tsujimura T, Iida O, Kobayashi T, Hamanaka Y, Omatsu T, Sakata Y, Higuchi Y, Mano T. Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation. Cardiovasc Diabetol 2020;19:203. [PMID: 33267863 DOI: 10.1186/s12933-020-01173-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, Kato T, Ando K, Nakagawa Y, Furukawa Y, Tada T, Nagao K, Kadota K, Toyofuku M, Kimura T; on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.119.008307] [Cited by in Crossref: 51] [Cited by in F6Publishing: 5] [Article Influence: 25.5] [Reference Citation Analysis]
112 Kim J, Jang WJ, Lee WS, Choi KH, Lee JM, Park TK, Yang JH, Choi JH, Song YB, Choi SH, Gwon HC, Lee SH, Oh JH, Chun WJ, Park YH, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Hahn JY. P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor. Heart 2021:heartjnl-2020-318821. [PMID: 33758008 DOI: 10.1136/heartjnl-2020-318821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Giacoppo D, Matsuda Y, Fovino LN, D'Amico G, Gargiulo G, Byrne RA, Capodanno D, Valgimigli M, Mehran R, Tarantini G. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2021;42:308-19. [PMID: 33284979 DOI: 10.1093/eurheartj/ehaa739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
114 Chatterjee M, Ehrenberg A, Toska LM, Metz LM, Klier M, Krueger I, Reusswig F, Elvers M. Molecular Drivers of Platelet Activation: Unraveling Novel Targets for Anti-Thrombotic and Anti-Thrombo-Inflammatory Therapy. Int J Mol Sci 2020;21:E7906. [PMID: 33114406 DOI: 10.3390/ijms21217906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
115 Kobo O, Mohamed MO, Farmer AD, Alraies CM, Patel T, Sharma K, Nolan J, Bagur R, Roguin A, Mamas MA. Outcomes of Percutaneous Coronary Intervention in Patients With Crohn's Disease and Ulcerative Colitis (from a Nationwide Cohort). Am J Cardiol 2020;130:30-6. [PMID: 32665130 DOI: 10.1016/j.amjcard.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
116 Hong SJ, Kim JS, Hong SJ, Lim DS, Lee SY, Yun KH, Park JK, Kang WC, Kim YH, Yoon HJ, Won H, Nam CM, Ahn CM, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; One-Month DAPT Investigators. 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial. JACC Cardiovasc Interv 2021;14:1801-11. [PMID: 34332946 DOI: 10.1016/j.jcin.2021.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Luo L, Fu M, Li Y, Chen Z, Yu J, Luo J, Hu S, Tu L, Xu X. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. Clin Cardiol 2020;43:235-41. [PMID: 31777973 DOI: 10.1002/clc.23305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
118 Capodanno D, Angiolillo DJ. When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y12 Inhibition Induced by Ticagrelor. J Am Heart Assoc 2020;9:e019432. [PMID: 33302757 DOI: 10.1161/JAHA.120.019432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Sinha N, Balayla G, Braghiroli J. Coronary artery disease in lung transplant patients. Clin Transplant 2020;34:e14078. [PMID: 32940380 DOI: 10.1111/ctr.14078] [Reference Citation Analysis]
120 Nagao A, Koganei H, Yamaguchi T, Fukutake K. Successful emicizumab prophylaxis during dual antiplatelet therapy for insertion of drug-eluting stents after acute coronary syndrome: A case report. Haemophilia 2021;27:e549-50. [PMID: 33780095 DOI: 10.1111/hae.14305] [Reference Citation Analysis]
121 Sulzgruber P. Changing paradigms in antiplatelet therapy after coronary intervention. Eur Heart J Cardiovasc Pharmacother 2021;7:206-8. [PMID: 32544246 DOI: 10.1093/ehjcvp/pvaa043] [Reference Citation Analysis]
122 Sato Y, Jinnouchi H, Kolodgie FD, Cheng Q, Janifer C, Kutyna M, Sakamoto A, Cornelissen A, Mori M, Kawakami R, Kawai K, Fernandez R, Ghosh SKB, Romero ME, Perkins LEL, Virmani R, Finn AV. Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. Int J Cardiol 2021;338:42-9. [PMID: 34174338 DOI: 10.1016/j.ijcard.2021.06.034] [Reference Citation Analysis]
123 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
124 Gupta K, Khan A, Kumar M, Sawalha K, Abozenah M, Singhania R. Readmissions Rates After Myocardial Infarction for Gastrointestinal Bleeding: A National Perspective. Dig Dis Sci 2021;66:751-9. [PMID: 32436123 DOI: 10.1007/s10620-020-06315-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Zeitouni M, Guedeney P. Aspirin-Free Strategies in ACS: Is It the Drug or the Stent? JACC Cardiovasc Interv 2021;14:441-3. [PMID: 33602440 DOI: 10.1016/j.jcin.2020.12.040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Matsumura-Nakano Y, Shiomi H, Morimoto T, Yamaji K, Ehara N, Sakamoto H, Takeji Y, Yoshikawa Y, Yamamoto K, Imada K, Tada T, Taniguchi R, Nishikawa R, Tada T, Uegaito T, Ogawa T, Yamada M, Takeda T, Eizawa H, Tamura N, Tambara K, Suwa S, Shirotani M, Tamura T, Inoko M, Nishizawa J, Natsuaki M, Sakai H, Yamamoto T, Kanemitsu N, Ohno N, Ishii K, Marui A, Tsuneyoshi H, Terai Y, Nakayama S, Yamazaki K, Takahashi M, Tamura T, Esaki J, Miki S, Onodera T, Mabuchi H, Furukawa Y, Tanaka M, Komiya T, Soga Y, Hanyu M, Ando K, Kadota K, Minatoya K, Nakagawa Y, Kimura T; On behalf the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators. Comparison of Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Among Patients With Three-Vessel Coronary Artery Disease in the New-Generation Drug-Eluting Stents Era (From CREDO-Kyoto PCI/CABG Registry Cohort-3). Am J Cardiol 2021;145:25-36. [PMID: 33454340 DOI: 10.1016/j.amjcard.2020.12.076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
127 Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-Zaleski I, Arnaiz JA, Martínez-Sellés M, Silvain J, Ariza-Solé A, Ferrari E, Calvo G, Danchin N, Avendaño-Solá C, Frenkiel J, Rousseau A, Vicaut E, Simon T, Steg PG; REALITY Investigators. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA 2021;325:552-60. [PMID: 33560322 DOI: 10.1001/jama.2021.0135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
128 Gamal AS, Hara H, Tomaniak M, Lunardi M, Gao C, Ono M, Kawashima H, Jüni P, Vranckx P, Windecker S, Hamm C, Steg PG, Onuma Y, Serruys PW. 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial. Eur Heart J Acute Cardiovasc Care 2021:zuab033. [PMID: 34212187 DOI: 10.1093/ehjacc/zuab033] [Reference Citation Analysis]
129 Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology 2020;75:1095-106. [DOI: 10.1016/j.jacc.2019.12.067] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
130 Loganath K, Adamson PD, Moss AJ. Ticagrelor in the management of coronary artery disease. Future Cardiol 2021;17:561-71. [PMID: 32960097 DOI: 10.2217/fca-2020-0108] [Reference Citation Analysis]
131 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med 2020;59:311-21. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
132 Ohgaku A, Fukamachi D, Takahashi K, Tamiya R, Migita S, Mizobuchi S, Miyagawa M, Koyama Y, Fujito H, Arai R, Ebuchi Y, Migita S, Morikawa T, Monden M, Takei N, Tamaki T, Kojima K, Akutsu N, Murata N, Kitano D, Okumura Y. Absence of coronary angioscopy-derived in-stent thrombi is associated with major bleeding events in acute myocardial infarction. Atherosclerosis 2021;319:62-71. [PMID: 33486352 DOI: 10.1016/j.atherosclerosis.2021.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Kleiman NS. Is This a Good Time to Revisit the Tropics?: Platelet Function Testing in Patients With Acute Coronary Syndromes. JACC Cardiovasc Interv 2021;14:428-30. [PMID: 33516695 DOI: 10.1016/j.jcin.2020.12.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Galli M, Capodanno D, Andreotti F, Crea F, Angiolillo DJ. Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin Drug Saf 2021;20:9-21. [PMID: 33180563 DOI: 10.1080/14740338.2021.1850691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
135 Yamamoto K, Watanabe H, Morimoto T, Domei T, Ohya M, Ogita M, Takagi K, Suzuki H, Nikaido A, Ishii M, Fujii S, Natsuaki M, Yasuda S, Kaneko T, Tamura T, Tamura T, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Igarashi Hanaoka K, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. Circ Cardiovasc Interv 2021;14:e010384. [PMID: 34003662 DOI: 10.1161/CIRCINTERVENTIONS.120.010384] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Lee RH, Kasthuri RS, Bergmeier W. Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions. Curr Opin Hematol 2020;27:378-85. [PMID: 32868672 DOI: 10.1097/MOH.0000000000000608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Wernly B, Rezar R, Gurbel P, Jung C. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint. J Thromb Thrombolysis 2020;49:173-6. [PMID: 31686298 DOI: 10.1007/s11239-019-01985-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
138 Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger J, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-ardilouze E, Boccara F, Labeque J, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet J, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G, Silvain J, Collet J, Montalescot G, Kerneis M, Braik N, Barthelemy O, Helft G, Lefeuvre C, Choussat R, Hauguel M, Zeitouni M, Cuisset T, Bonnet J, Deharo P, Lattuca B, Cayla G, Cornillet L, Ledermann B, Lonjon C, Schmutz L, Range G, Albert F, Demicheli T, Roussel L, Bensaid R, Thuaire C, Dillinger J, Henry P, Manzo-silberman S, Sideris G, Logeart D, Spagnoli V, Cacoub L, Pouillot C, Vi-fane JR, Glasenapp J, Bougrini K, Combaret N, Motreff P, Souteyrand G, Amonchot A, Mouyen T, Lhermusier T, Carrie D, Bouisset F, Chollet T, Campelo-parada F, Delarche N, Schiele F, Besutti M, Hauguel-moreau M, El Mahmoud R, Caussin C, Zoheir M, Veugeois A, Dibie A, Varenne O, Picard F, Lafont A, Adjedj J, Degrell P, Beygui F, Sabatier R, Roule V, Bignon M, Blanchart K, Ardouin P, Lemaitre A, Briet C, Boueri Z, Goube P, Coste P, Cetran L, Clerc J, Le Breton H, Boulmier D, Auffret V, Labeque J, Bonas J, Georges J, Livarek B, Blicq E, Baron N, Gibault-genty G, Cottin Y, Lhuillier I, Richard C, Lorgis L, Buffet P, Spaulding C, Karam N, Puymirat E, Mennuni M, Poulidakis E, Bonnevie L, Boccara F, Chauvet M, Dufour L, Ancedy Y, Ederhy S, Etienney A, Bellemain-appaix A, Bitton N, Jacq L, Saint-etienne C, Leclercq F, Roubille F, Rioufol G, Derimay F, Goralski M, Yafi W, Filippi E, Kermarrec A, Le Ray C, Merlet A, Loirat A, Brunel P, Brunet D, Ravisy J, Mock L, Molins G, Carre M, Bressollette E, Christiaens L, Larrieu-ardilouze E, Cador RC, Van Belle E, Lemesle G, Delhaye C, Vincent F, Porouchani S, Spillemaeker H, Petit K, Ressencourt O, Carre M, Humeau V, Jourda F, Arnould M, Chassaing S, Isaaz K, Payot L, Montsegu J, Faurie B, Pansieri M, Metge M, Moussa K, Pankert M, Morel O, Hess S, Maillard L, Manigold T, Letocart V, Plessis J, Berthome P, Bonin M, Huchet F, Teiger E, Gallet R, Mouillet G, Boukantar M, El Mahmoud R, Nejjari M, Attias D, Cacoub L, Steinecker M, Huchet F, Motovska Z, Kozel M, Stelmach Z, Hlinomaz O, Rezek M, Novak M, Sitar J, Semenka J, Kala P, Bocek O, Štipal R, Poloczek M, Kanovský J, Jerabek P, Karasek J, Hruskova S, Branny M, Mrozek J, Grezl T, Pleva L, Kukla P, Porzer M. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. The Lancet 2020;396:1737-44. [DOI: 10.1016/s0140-6736(20)32236-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
139 Takahashi K, Wang R, Kawashima H, Tomaniak M, Gao C, Ono M, Hara H, Wykrzykowska JJ, de Winter RJ, Werner N, Teiger E, Almeida M, Barraud P, Lantelme P, Barlis P, Garg S, Hamm C, Steg PG, Onuma Y, Vranckx P, Windecker S, Valgimigli M, Serruys PW. Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. Int J Cardiol 2020;320:27-34. [PMID: 32750393 DOI: 10.1016/j.ijcard.2020.07.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; On behalf of the STOPDAPT-2 Investigators. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial. Circulation 2019;140:1957-9. [DOI: 10.1161/circulationaha.119.043613] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
141 Kuno T, Ueyama H, Takagi H, Bangalore S. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials. Am Heart J 2020;227:82-90. [PMID: 32693196 DOI: 10.1016/j.ahj.2020.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
142 Patti G, Fattirolli F, De Luca L, Renda G, Marcucci R, Parodi G, Perna GP, Andreotti F, Ghiglieno C, Fedele F, Marchionni N. Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. Biomed Pharmacother 2021;140:111783. [PMID: 34102448 DOI: 10.1016/j.biopha.2021.111783] [Reference Citation Analysis]
143 Valgimigli M, Cao D, Makkar RR, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Ge J, Neumann FJ, Hermiller J, Picon H, Toelg R, Maksoud A, Chehab BM, Wang LJ, Wang J, Mehran R. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. Am Heart J 2021;231:147-56. [PMID: 33031789 DOI: 10.1016/j.ahj.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
144 Numasawa Y, Sawano M, Fukuoka R, Ejiri K, Kuno T, Shoji S, Kohsaka S. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. J Clin Med 2020;9:E1963. [PMID: 32585929 DOI: 10.3390/jcm9061963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
145 Li J, He K, Ge J, Li C, Jing Z. Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Int J Clin Pract 2021;75:e13938. [PMID: 33341109 DOI: 10.1111/ijcp.13938] [Reference Citation Analysis]
146 Angiolillo DJ, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, Mehta S, Briguori C, Cohen DJ, Collier T, Dudek D, Escaned J, Gibson CM, Gil R, Huber K, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Moliterno DJ, Ohman EM, Oldroyd K, Sardella G, Sharma SK, Shlofmitz R, Weisz G, Witzenbichler B, Pocock S, Mehran R. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC Cardiovasc Interv 2021;14:1434-46. [PMID: 34238553 DOI: 10.1016/j.jcin.2021.04.043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y; PENDULUM Registry Investigators*. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry. J Am Heart Assoc 2020;9:e015439. [PMID: 32394794 DOI: 10.1161/JAHA.119.015439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
148 Park HW, Kang MG, Ahn JH, Bae JS, Tantry US, Gurbel PA, Jeong YH. Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. J Clin Med 2021;10:2720. [PMID: 34202960 DOI: 10.3390/jcm10122720] [Reference Citation Analysis]
149 Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, Sawan M, Sato Y, Cornelissen A, Kuntz SH, Kutyna M, Paek KH, Fernandez R, Braumann R, Mont EK, Surve D, Romero ME, Kolodgie FD, Virmani R, Finn AV. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J 2020;41:786-96. [PMID: 31803916 DOI: 10.1093/eurheartj/ehz850] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
150 Luo CF, Mo P, Li GQ, Liu SM. Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. Eur Heart J Cardiovasc Pharmacother 2021;7:218-24. [PMID: 32129850 DOI: 10.1093/ehjcvp/pvaa016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
151 Garg A, Rout A, Sharma A, Sargsyan D, Beavers T, Tantry U, Gurbel P, Rao SV, Kostis JB, Cohen M. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. Progress in Cardiovascular Diseases 2020;63:243-8. [DOI: 10.1016/j.pcad.2020.03.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
152 Jinnouchi H, Sato Y, Cheng Q, Janifer C, Kutyna M, Cornelissen A, Wijeratne R, Sakamoto A, Guo L, Kolodgie FD, Tunev S, Virmani R, Finn AV. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. Int J Cardiol 2021;327:52-7. [PMID: 33242506 DOI: 10.1016/j.ijcard.2020.11.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
153 Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R, Kogame N, Magro M, Chowdhary S, Eitel I, Zweiker R, Ong P, Ottesen MM, Tijssen JG, Wykrzykowska JJ, de Winter RJ, Garg S, Stoll H, Hamm C, Steg PG, Onuma Y, Valgimigli M, Vranckx P, Carrie D, Windecker S. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. Journal of the American College of Cardiology 2019;74:2015-27. [DOI: 10.1016/j.jacc.2019.08.997] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
154 Nicolas J, Razuk V, Giustino G, Mehran R. Current state-of-the-art antiplatelet and anticoagulation therapy in diabetic patients with coronary artery disease. Future Cardiol 2021;17:521-34. [PMID: 33728965 DOI: 10.2217/fca-2021-0014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Takeji Y, Shiomi H, Morimoto T, Yoshikawa Y, Taniguchi R, Mutsumura-Nakano Y, Yamamoto K, Yamaji K, Tazaki J, Kato ET, Watanabe H, Yamamoto E, Yamashita Y, Fuki M, Suwa S, Inoko M, Takeda T, Shirotani M, Ehara N, Ishii K, Inada T, Tamura T, Onodera T, Shinoda E, Yamamoto T, Watanabe H, Yaku H, Nakatsuma K, Sakamoto H, Ando K, Soga Y, Furukawa Y, Sato Y, Nakagawa Y, Kadota K, Komiya T, Minatoya K, Kimura T; CREDO-Kyoto AMI Registry Wave-1 and the CREDO-Kyoto AMI Registry Wave-2 Investigators. Changes in demographics, clinical practices and long-term outcomes of patients with ST segment-elevation myocardial infarction who underwent coronary revascularisation in the past two decades: cohort study. BMJ Open 2021;11:e043683. [PMID: 33789850 DOI: 10.1136/bmjopen-2020-043683] [Reference Citation Analysis]
156 Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother 2020:pvaa106. [PMID: 32941620 DOI: 10.1093/ehjcvp/pvaa106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
157 Takeji Y, Shiomi H, Morimoto T, Yoshikawa Y, Taniguchi R, Mutsumura-Nakano Y, Yamamoto K, Yamaji K, Tazaki J, Suwa S, Inoko M, Takeda T, Shirotani M, Ehara N, Ishii K, Inada T, Onodera T, Shinoda E, Yamamoto T, Tamura T, Nakatsuma K, Sakamoto H, Ando K, Soga Y, Furukawa Y, Sato Y, Nakagawa Y, Kadota K, Komiya T, Minatoya K, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 and the CREDO-Kyoto PCI/CABG Registry Cohort-3 Investigators. Demographics, practice patterns and long-term outcomes of patients with non-ST-segment elevation acute coronary syndrome in the past two decades: the CREDO-Kyoto Cohort-2 and Cohort-3. BMJ Open 2021;11:e044329. [PMID: 33619198 DOI: 10.1136/bmjopen-2020-044329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Zhang J, Chen S. IVUS Guidance for Coronary Revascularization. JACC: Cardiovascular Interventions 2020;13:72-3. [DOI: 10.1016/j.jcin.2019.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-garcia HM, Waksman R. Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. The American Journal of Cardiology 2020;135:154-65. [DOI: 10.1016/j.amjcard.2020.07.061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
160 Shiomi H, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yoshikawa Y, Yamaji K, Tada T, Tazaki J, Ehara N, Taniguchi R, Tamura T, Iwakura A, Tada T, Watanabe H, Suwa S, Toyofuku M, Inada T, Kaneda K, Ogawa T, Takeda T, Sakai H, Yamamoto T, Tambara K, Esaki J, Eizawa H, Yamada M, Shinoda E, Nishizawa J, Mabuchi H, Tamura N, Shirotani M, Nakayama S, Uegaito T, Matsuda M, Takahashi M, Inoko M, Kanemitsu N, Tamura T, Ishii K, Nawada R, Onodera T, Ohno N, Koyama T, Tsuneyoshi H, Sakamoto H, Aoyama T, Miki S, Tanaka M, Sato Y, Yamazaki F, Hanyu M, Soga Y, Komiya T, Ando K, Minatoya K, Kimura T. Coronary Revascularization in the Past Two Decades in Japan (From the CREDO-Kyoto PCI/CABG Registries Cohort-1, -2, and -3). Am J Cardiol 2021;153:20-9. [PMID: 34238444 DOI: 10.1016/j.amjcard.2021.05.015] [Reference Citation Analysis]
161 Galli M, Angiolillo DJ. Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. Curr Opin Cardiol 2021;36:390-6. [PMID: 33973929 DOI: 10.1097/HCO.0000000000000879] [Reference Citation Analysis]
162 Lee SJ, Cho JY, Kim BK, Yun KH, Suh Y, Cho YH, Kim YH, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon HM, Hong SJ, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Interv 2021;14:431-40. [PMID: 33602439 DOI: 10.1016/j.jcin.2020.11.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
163 Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020;323:2407-16. [PMID: 32543684 DOI: 10.1001/jama.2020.7580] [Cited by in Crossref: 98] [Cited by in F6Publishing: 71] [Article Influence: 98.0] [Reference Citation Analysis]
164 Chau KH, Kirtane AJ, Easterwood RM, Redfors B, Zhang Z, Witzenbichler B, Weisz G, Stuckey TD, Brodie BR, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Mehran R, Stone GW. Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES. JACC Cardiovasc Interv 2021;14:417-27. [PMID: 33516690 DOI: 10.1016/j.jcin.2020.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
165 Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, Stefanini GG, Angiolillo DJ, Capodanno D, Urban P, Morice M, Krucoff M, Goel R, Roumeliotis A, Sweeny J, Sharma SK, Kini A. Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology 2020;75:2711-22. [DOI: 10.1016/j.jacc.2020.03.070] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 47.0] [Reference Citation Analysis]
166 Jin Y, Huang H, Shu X, Chen S, Lu L, Gao X, Wu Z. P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials. Thromb Res 2021;198:115-21. [PMID: 33316640 DOI: 10.1016/j.thromres.2020.11.038] [Reference Citation Analysis]
167 Hara H, van Klaveren D, Takahashi K, Kogame N, Chichareon P, Modolo R, Tomaniak M, Ono M, Kawashima H, Wang R, Gao C, Niethammer M, Fontos G, Angioi M, Ribeiro VG, Barbato E, Leandro S, Hamm C, Valgimigli M, Windecker S, Jüni P, Steg PG, Verbeeck J, Tijssen JGP, Sharif F, Onuma Y, Serruys PW; GLOBAL LEADERS Trial Investigators. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circ Cardiovasc Qual Outcomes 2020;13:e006660. [PMID: 32762446 DOI: 10.1161/CIRCOUTCOMES.120.006660] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
168 Kogame N, Guimarães PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, Kawashima H, Ono M, Hara H, Wang R, Cavalcante R, Moulin B, Falcão BA, Leite RS, de Almeida Sampaio FB, Morais GR, Meireles GC, Campos CM, Onuma Y, Serruys PW, Lemos PA. Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. JACC: Cardiovascular Interventions 2020;13:2251-62. [DOI: 10.1016/j.jcin.2020.06.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
169 Chandrasekhar J, Baber U, Sartori S, Aquino MB, Hájek P, Atzev B, Hudec M, Kiam Ong T, Mates M, Borisov B, Warda HM, den Heijer P, Wojcik J, Iniguez A, Coufal Z, Khashaba A, Munawar M, Gerber RT, Yan BP, Tejedor P, Kala P, Bang Liew H, Lee M, Kalkman DN, Dangas GD, de Winter RJ, Colombo A, Mehran R; MASCOT investigators. 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry.Int J Cardiol Heart Vasc. 2020;31:100605. [PMID: 32953969 DOI: 10.1016/j.ijcha.2020.100605] [Reference Citation Analysis]
170 Kumar A, Shariff M, Doshi R, Vaz IP. Abbreviated Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 12 Months' Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs 2020;20:355-61. [PMID: 31784888 DOI: 10.1007/s40256-019-00390-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Capodanno D, Angiolillo DJ. Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation 2020;142:2172-88. [PMID: 33253005 DOI: 10.1161/CIRCULATIONAHA.120.045465] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
172 Goto S, Goto S. Is the answer to clinical questions provided by Bayesian network meta-analysis? Regarding the optimal duration of DAPT and the best subsequent SAPT. Eur Heart J Cardiovasc Pharmacother 2021;7:216-7. [PMID: 32424398 DOI: 10.1093/ehjcvp/pvaa032] [Reference Citation Analysis]
173 Biswas M, Rahaman S, Biswas TK, Ibrahim B. Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: A systematic review and meta-analysis. Expert Opin Drug Saf 2020;19:1605-16. [PMID: 33040624 DOI: 10.1080/14740338.2020.1836152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
174 Watanabe H, Morimoto T, Ogita M, Suwa S, Natsuaki M, Suematsu N, Koeda Y, Morino Y, Nikaido A, Hata Y, Doi M, Hibi K, Kimura K, Yoda S, Kaneko T, Nishida K, Kawai K, Yamaguchi K, Wakatsuki T, Tonoike N, Yamamoto M, Shimizu S, Shimohama T, Ako J, Kimura T; STOPDAPT-2 Investigators. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. Cardiovasc Interv Ther 2021;36:403-15. [PMID: 33184726 DOI: 10.1007/s12928-020-00719-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Kim HK, Tantry US, Park HW, Shin ES, Geisler T, Gorog DA, Gurbel PA, Jeong YH. Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. Korean Circ J 2021;51:202-21. [PMID: 33655720 DOI: 10.4070/kcj.2020.0537] [Reference Citation Analysis]
176 Bianco M, Careggio A, Destefanis P, Luciano A, Perrelli MG, Quadri G, Rossini R, Campo G, Vizzari G, D'Ascenzo F, Anselmino M, Biondi-Zoccai G, Ibáñez B, Montagna L, Varbella F, Cerrato E. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J Cardiovasc Pharmacother 2021;7:196-205. [PMID: 32544220 DOI: 10.1093/ehjcvp/pvaa038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
177 Kandzari DE, Kirtane AJ, Windecker S, Latib A, Kedhi E, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Choi JW, Caputo R, Kanitkar M, McLaurin B, Potluri S, Smith T, Spriggs D, Tolleson T, Nazif T, Parke M, Lee LC, Lung TH, Stone GW; Onyx ONE US/Japan Investigators. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv 2020;13:e009565. [PMID: 33167705 DOI: 10.1161/CIRCINTERVENTIONS.120.009565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
178 Khan SU, Osman M, Khan MU, Khan MS, Zhao D, Mamas MA, Savji N, Al-Abdouh A, Hasan RK, Michos ED. Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Ann Intern Med 2020;172:474-83. [PMID: 32176890 DOI: 10.7326/M19-3763] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 15.0] [Reference Citation Analysis]
179 Mangieri A, Gallo F, Sticchi A, Khokhar AA, Laricchia A, Giannini F, Colombo A. Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. Cardiovasc Interv and Ther 2020;35:117-29. [DOI: 10.1007/s12928-020-00642-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
180 Gimbel ME, Ten Berg JM. Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome. Expert Opin Drug Saf 2021;:1-8. [PMID: 34106029 DOI: 10.1080/14740338.2021.1936498] [Reference Citation Analysis]